| 3 -0.01 (-0.33%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.72 | 1-year : | 3.91 |
| Resists | First : | 3.18 | Second : | 3.34 |
| Pivot price | 3.08 |
|||
| Supports | First : | 2.93 | Second : | 2.43 |
| MAs | MA(5) : | 3 |
MA(20) : | 3.08 |
| MA(100) : | 2.27  |
MA(250) : | 2.27 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 18.7 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 8.47 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CYCN ] has closed above bottom band by 22.9%. Bollinger Bands are 76% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.1 - 3.12 | 3.12 - 3.13 |
| Low: | 2.94 - 2.96 | 2.96 - 2.98 |
| Close: | 2.97 - 3 | 3 - 3.03 |
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Tue, 09 Jun 2026
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
Fri, 01 May 2026
CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mon, 20 Apr 2026
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline - Yahoo Finance
Thu, 02 Apr 2026
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - WFXG
Thu, 02 Apr 2026
Cyclerion and Korsana Tie the Knot with a New Merger Strategy - StocksToTrade
Wed, 01 Apr 2026
Cyclerion provides public listing vehicle for Korsana in $380M deal - The Business Journals
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 267 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.6 |
| Profit Margin | -264.8 % |
| Operating Margin | -337.5 % |
| Return on Assets (ttm) | -45.9 % |
| Return on Equity (ttm) | -67.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.23 |
| Sales Per Share | 0.45 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.3 |
| PEG Ratio | 0 |
| Price to Book value | 1.87 |
| Price to Sales | 6.52 |
| Price to Cash Flow | -3.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|